<i>Aspidosperma subincanum</i> II. Usefulness of uleine and ribonucleic fragments in the treatment of AIDS patients

Maes, Dominique; Maes, Roland

doi:10.1016/j.bjp.2014.11.011

Acessibilidade / Reportar erro

Brasil

Revista Brasileira de Farmacognosia

Español English

Brasil

Español English

sumário « anterior atual seguinte »

Sumário

Original Articles • Rev. bras. farmacogn. 25 (1) • Jan-Feb 2015 • https://doi.org/10.1016/j.bjp.2014.11.011 copy

Aspidosperma subincanum II. Usefulness of uleine and ribonucleic fragments in the treatment of AIDS patients

Authorship SCIMAGO INSTITUTIONS RANKINGS

Aids patients were treated during a year with three different food supplements commercially available: para-pau-aspido (Aspidosperma subincanum Mart. ex A. DC., Apocynaceae); 2Leid (nucleic acids and cytokines); and Para Immuno (propolis, pollen and royal jelly). All foods, given either alone or in combination, proved useful to all AIDS patients who received the supplements, be these under tri-therapy (Triomine: stavudine, lamivudine, névirapine) or left unattended.

Uleine; HIV; Tri-therapy; Ribonucleic Acid Oligomers (RNO)

	Patient			Treatment			Symptoms	Weight				Viral L	CD4		Lymphocytes
N°	File	Age	Sex	PP	2Leid	P.I.	T0	T-1	T0	T3	T12	T-1	T-1	T0	T0	T3	T12
1	LB 42	19	F	80	yes	yes	3, 5, 16, 17		30	45	51			6	212	2915	3600
2	LA02	26	F	80	yes	yes	3,6,5	55	50	62	69	120000	84	80	131	2760
3	LA49	34	F	80	yes	yes	very bad	46	51	62	70	125000	25	24	802	2615
4	LA50	36	F	80	yes	yes	very bad	56	62	72	83	125000	62	56	904	2464
5	LA18	20	F	80	yes		3,4, very bad	44	45	60	80	140000	34	2	151	1768	2916
6	LB41	20	M	80	yes		3,4, very bad	60	60	61	66	0	611	90	402	1915	2690
7	LA32	32	F	80	yes		3,4, very bad	44	46	56	60	98650	245	40	806	2900	3050
8	LA35	37	F	80	yes		3,4, very bad	47	55	72	79	150000	16	127	679	2464
9	LB33	12	F	80			Conserved		30	32	53			191	720	1920	4500
10	La15	21	F	80			conserved state	59	60	65	76	20000	200	204	1504	2115	3915
11	LA06	30	F	80			2,3, 5, 6	46	40	53	67	120000	95	59	300	1584	3900
12	LA23	31	F	80			3, 13,6,5,	55	50	66	75	135000	50	60	800	2160	3916
13	LA31	15	F	20		yes	3, 6, 5	24	26	33	40	0	435	100	802	2005	3050
14	LA07	23	F		yes		6, 3, 11	45	40	52	64	10 000	300		1401	2500	3900

	Patient			Treatment			Symptoms	Weight			Viral L.	CD4			lymphocytes
N°	File	Age	Sex	P.P.	2Leid	P.I.	T0	T-1	T0	T3	T12	T-1	T-1	T0	T0	T3	T12
15	LB52	15	F	80	yes	yes	3, 6, bad	45	30	35	45	0	610		924	1802	2720
16	LC03	17	F	80	yes	yes	conserved		44	54	60				1121	3915
17	LB64	19	F	80	yes	yes	conserved		58	69	73				1215	2280
18	LB60	20	F	80	yes	yes	good state	59	50	60	65	0	488		1320	3916	4200
19	LA21	23	F	80	yes	yes	good state	51	54	60	66	75000	95	420	1420	2850	3915
20	LA36	31	F	80	yes	yes	good state	60	65	73	81	0	500	318	1412	4080
21	LC02	35	F	80	yes	yes	3,6, 14, bad		40	42	76				902
22	LB23	20	F	80	yes		conserved	60	65	70	74	6000	296	315	1390	2500	3920
23	LA20	21	F	80	yes		+/-' good	48	52	58	64	122000	50	105	1240	1539	2620
24	LA39	35	F	80	yes		conserved	40	45	65	75	120000	25	312	1219	2900	3620
25	LC04		M	80	yes		3, 6, 17		50	60	65				502	2108
26	LB30	20	F	80			conserved	35	50	61	66	10000	205	310	1311	2530	3910
27	LB19	20	F	80			good state	60	65	66	75	0	391	320	1301	1320	3900
28	LA33	30	F	80			conserved	46	50	60	65	100050	250	360	1250	2500	3200
29	LA13	3	F	20	yes	yes	3, 6, 5, 12	6	7	12	18	130 000	80	60	1201	2100	4610
30	LA45	3	F	20	yes	yes	good state	7	12	17	23	125000	25	391	1210	4608	5105
31	LA26	9	M	20	yes	yes	good state	14	16	20	36	0	420	402	1240	2100	4112
32	LA08	10	F	20	yes	yes	6, 3, 7, 4, 9	21	21	30	46	6 000	300	277	1314	3915	4904
33	LA44	10	F	20	yes	yes	good state	14	20	30	37	125000	85	420	1311	3016	3620
34	LA05	12	F	20	yes	yes	1, 6, 3, 8	28	29	35	51	12 000	250	277	1360	3005	4915
35	LA09	12	F	20	yes	yes	1, 9, 4	25	25	38	45	0	350	244	1901	2615	3916
36	LB53	13	M	20	yes	yes	very bad		13	20	25				612	3360	4600
37	LA04	14	F	20	yes	yes	5, 8	31	28	35	43	.50.000	140	130	1211	2900	4190
38	LA40	14	F	20	yes	yes	good state	16	20	30	46	53500	250	305	1229	3050	4215
39	LA01	11	M	20		yes	2,3, 4, 5, 10	26	24	30	35	80 500	120	100	711	2110
40	LB46	21	F	20		yes	conserved		59	65	75			226	1247	3024	4500
41	LA27	4	M	20	yes		good	11	11	15	21	0	500	305	1321	1910	2915
43	LA41	10	M	20	yes		good	16	20	26	40	25000	350	315	1319	3600	4250
44	LA17	11	M	20	yes		+/-' good	15	20	25	35	130000	100	60	405	1120	2905
45	LA30	13	M	20	yes		conserved	19	21	31	36	0	600	372	1120	2820	3912
46	LA03	15	F	20	yes		3,7	45	41	50	60	110 000	91	300	1707	2910	4210
47	LA43	9	F	20			good	13	20	25	36	15000	350	416	1620	2600	3950
48	LA29	11	M	20			conserved	24	25	30	36	0	480	450	1200	2912	4045
49	LB35	12	F	20			conserved	19	22	29	35	0	412	383	827	1460	2920
50	LB32	13	F	20			Conserved	30	32	40	45	5000	490	259	561	1768	2900
51	LB13	19	M	20			good state	60	62	75	79	0	526	620	1302	4901
52	LA10	21	F		yes	yes		60	55	61	72	30 000	200		1500	2500	4600
53	LB04	3	F		yes		3	12	12	15	26	0	710		1400	3500
54	LB02	4	F		yes		3,6, delayed growth	12	13	18	24	0	420		1830	2930
55	LB17	5	F		yes		3, 15, 14	18	18	25	30	0	518		1150	3900	4600
56	LB08	7	F		yes		6,14	18	18	25	37	0	520		1200	4500
57	LB21	21	F		yes		3, 6, 7	60	42	45	50	0	620		1950	2500	3600
58	LA25	25	F		yes		3,4,14	44	45	60	65	10000	360		1300	3900	4115
59	LA22	26			yes		conserved state	55	50	61	67	8000	300		1200	2700	4105
60	LA47	33	F		yes		3, 6, 5 tuberc.	52	51	61	71	5500	350		1250	2950	3920
	LA38	33	M		yes		conserved state	46	46	55	66	60000	300		1220	2915	2400

Sociedade Brasileira de Farmacognosia Universidade Federal do Paraná, Laboratório de Farmacognosia, Rua Pref. Lothario Meissner, 632 - Jd. Botânico, 80210-170, Curitiba, PR, Brasil, Tel/FAX (41) 3360-4062 - Curitiba - PR - Brazil
E-mail: revista@sbfgnosia.org.br

Acompanhe os números deste periódico no seu leitor de RSS

[1] *Corresponding author. E-mail: anda.mars@wanadoo.fr (R. Maes).